Santarus Pharming, Announce New Data from Open-Label Repeat Treatment Study with RUCONEST

Santarus (NASDAQ:

) and Pharming Group NV (OTC:

) announced that new data from an open-label extension of the pivotal Phase III clinical study with RUCONEST® (recombinant human C1 esterase inhibitor, or rhC1INH) will be featured in a poster presentation on November 9 & 10, 2013 at the 2013 American College of Allergy, Asthma & Immunology Annual Scientific Meeting at the Convention Center in Baltimore, Maryland. The poster is titled, Efficacy and Safety of Recombinant Human C1 Esterase Inhibitor for Acute Attacks of Hereditary Angioedema: An Open-Label Study. RUCONEST was administered for the treatment of 224 repeat acute angioedema attacks in 44 patients with hereditary angioedema (HAE) following initial treatment